Treatment outcome of combination therapy including clarithromycin for Mycobacterium avium complex pulmonary disease.
Korean J Intern Med
; 26(1): 54-9, 2011 Mar.
Article
em En
| MEDLINE
| ID: mdl-21437163
ABSTRACT
BACKGROUND/AIMS:
The frequency of nontuberculous mycobacteria pulmonary disease in HIV-negative patients is increasing; the most common pathogen in Korea is the Mycobacterium avium complex (MAC). However, few studies have evaluated the treatment outcome of MAC pulmonary disease in Korea.METHODS:
The efficacy of a clarithromycin-containing regimen for MAC pulmonary disease was studied in 42 patients treated for more than 6 months between January 2005 and December 2008. All patients were treated with a regimen consisting of clarithromycin, rifampin, and ethambutol. Streptomycin was added in 10 patients.RESULTS:
Among the 42 patients, a negative culture conversion was achieved in 33 (78.6%), and the median duration of treatment in these patients was 19 months (interquartile range [IQR], 16 to 22). Of the 33 patients with a negative culture conversion, 14 completed treatment. During the follow-up period (median, 10 months; IQR, 4 to 20) for the 14 patients, one relapsed at 24 months after treatment completion. The culture conversion rate was significantly higher in patients who were treated with more than 500 mg/day clarithromycin (87.1% vs. 54.5%, p = 0.038).CONCLUSIONS:
The combined regimen including clarithromycin was effective against MAC pulmonary disease. High-dose clarithromycin of more than 500 mg/day may improve the outcome of patients with MAC pulmonary disease.Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Infecção por Mycobacterium avium-intracellulare
/
Claritromicina
/
Pneumopatias
/
Antibacterianos
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Korean J Intern Med
Assunto da revista:
MEDICINA INTERNA
Ano de publicação:
2011
Tipo de documento:
Article